Ask a Neuroscientist: Cannabis and Migraines

Alcohol is also a known trigger. About one-third of people with migraine say alcohol has set off an attack at least sometimes, with red wine most often implicated — through histamine release, changes in blood vessels, and effects on the serotonin system.

Cannabis users in the research consistently report the opposite: inhaled cannabis is associated with headache and migraine reduction rather than provocation.

Women and Migraines

Migraine affects women two to three times as often as men. The gap appears at puberty and shrinks after menopause. Estrogen is central to why. The drop in estrogen before menstruation is one of the most reliable migraine triggers known — predictable enough that some women can set a calendar by it.

Research has also found that estrogen affects how actively the endocannabinoid system operates. Higher estrogen is linked to greater CB1 receptor activity — the same receptor cannabis targets. Women’s migraine biology and their response to cannabis may not be fully separable from their hormonal profile.

Your Brain’s Own Cannabis System

Your brain has its own built-in cannabis-like system: the endocannabinoid system, or ECS. In 1992, a research team led by Israeli chemist Raphael Mechoulam discovered the brain’s first known cannabis-like molecule. Mechoulam’s lab had also first isolated THC from cannabis in the 1960s. They named it anandamide, from ananda, the Sanskrit word for bliss. The second major molecule is called 2-AG. Both work by fitting into receptors called CB1 and CB2, distributed throughout the brain and nervous system.

CB1 Receptors

CB1 receptors are found in high concentrations in parts of the brain that control pain — among the most densely packed receptor types in those regions. One important area is the periaqueductal gray, a pain-control center deep in the brain. Another is the trigeminal nucleus caudalis, where pain signals from the head and face first get processed.

Research has shown that CB1 activity can block CGRP release from the nerve fibers involved in migraine, directly targeting the chemical at the center of migraine pain. CB1 receptors in the brainstem also interact with serotonin pathways in a way that overlaps with how triptans work.

Clinical Endocannabinoid Deficiency

In 2004, neurologist Ethan Russo proposed that migraine, fibromyalgia (widespread body pain), and irritable bowel syndrome might share one underlying problem: not enough ECS activity. He called this Clinical Endocannabinoid Deficiency, or CECD.

His idea: when the body’s own cannabis-like system runs too low, the ability to manage pain, gut function, and mood suffers. Cannabis from outside the body might help restore it. CECD has not been proven. But it gives researchers a biologically grounded way to think about why cannabis might help migraine differently from standard pain medicines.

THC and Migraines

THC, the main active compound in cannabis, works by mimicking anandamide. It is structurally similar enough to fit the same CB1 receptors and produce many of the same effects. When anandamide fits a CB1 receptor, it can reduce pain and calm inflammation. THC fits the same receptor and does the same thing. This is the core reason the ECS became a target of interest for migraine research.

Research on Cannabis and Migraines

The biggest study on cannabis and migraine came out in 2020. Researchers at Washington State University, led by Dr. Carrie Cuttler, analyzed data from Strainprint, a phone app that let medical cannabis patients rate their symptoms before and after using cannabis. More than 1,300 people tracked headaches and 653 tracked migraines, making nearly 20,000 entries together.

Notable findings include:

• Inhaled cannabis was linked to a 47.3% drop in headache pain and a 49.6% drop in migraine pain on average.
• Concentrates produced larger headache reductions than flower.
• Over repeated sessions, flower users needed increasing doses to achieve the same relief, while concentrate doses held steady or decreased.
• Higher THC content was specifically associated with greater headache reduction.
• Men reported larger headache reductions than women
• More women than men reported that cannabis made their headache worse.
• The role of CBD in migraine remains much less clear.

The study found no evidence of medication overuse headache in the self-report data, though this type of data cannot rule it out.

A key limitation: people who found cannabis unhelpful would stop using the app, inflating the results upward. Cuttler acknowledged this and called for placebo-controlled trials. The data also covers only inhaled cannabis — smoked flower and vaporized concentrates. How edibles and other oral forms affect migraine is a separate question with no comparable data yet.

The Rebound Risk of Cannabis and Migraines

One risk is easy to overlook: using any pain medicine too often can cause more headaches.

When the brain receives external pain relief regularly, it gradually dials back its own internal pain-control activity. The pain system becomes less responsive over time. When the medicine wears off, pain returns at a lower threshold than before. Doctors call this medication overuse headache, or MOH — also known as rebound headache. It happens with triptans, opioids, and anti-inflammatory drugs.

Evidence suggests cannabis can cause the same problem. A 2021 Stanford study looked at patients with chronic migraine — defined as 15 or more migraine days per month for at least a year. Cannabis users in that group were nearly six times more likely to have MOH (odds ratio 5.99; 95% CI 3.45–10.43). The study was backward-looking — we cannot tell which came first — but the link was strong.